# Safety and Immunogenicity of Clade C ALVAC and gp120 HIV Vaccine

> **NCT03284710** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 132 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **BIOLOGICAL:** ALVAC-HIV (vCP2438)
- **BIOLOGICAL:** Bivalent Subtype C gp120/MF59
- **BIOLOGICAL:** Bivalent Subtype C gp120 admixed with Al(OH)3 Suspension
- **BIOLOGICAL:** Bivalent Subtype C gp120

## Key facts

- **NCT ID:** NCT03284710
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-19
- **Primary completion:** 2019-12-12
- **Final completion:** 2019-12-12
- **Target enrollment:** 132 (ACTUAL)
- **Last updated:** 2026-05-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03284710

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03284710, "Safety and Immunogenicity of Clade C ALVAC and gp120 HIV Vaccine". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03284710. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*